Conclusion: OS and PFS outcomes were superior to those observed in prior studies evaluating sorafenib alone in patients with a similar disease status, warranting further study of this treatment combination.
://www.dovepress.com/yttrium-90-resin-microspheres-as-an-adjunct-to-sorafenib-in-patients-w-peer-reviewed-article-JHC
Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellula
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $80.64M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $357.0K | 1.868M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 756388 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 300000 | 3 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |